LINKÖPING, Sweden, March 22, 2023 — AMRA researchers together with Linköping University and Virginia Commonwealth University conducted a large, observational study to…
Medical Research
AMRA Medical at AASLD 2022: Premier MRI Technology and Informatics for The Full Continuum of Liver Disease
AMRA Medical’s MRI-based technology and informatics are featured in seven abstracts accepted for presentation at The Liver Meeting 2022 – the world’s “must-attend” hepatology meeting.
AMRA Medical at EASD 2022 Conference: Two Abstracts Paving A New Path For Research With The Two Largest Diabetes Companies
AMRA Medical’s cutting-edge technology for body composition assessment was used in two separate studies for evaluating the effects of diabetes drugs—one being Lilly’s Tirzepatide, the other Novo Nordisk’s Liraglutide.
Fulcrum Phase 3 FSHD Clinical Trial Using AMRA Medical’s Whole-body MRI Measurements as a Key Secondary Endpoint
REACH, a Phase 3 Clinical Trial of losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) utilizes AMRA’s Muscle Fat Infiltration (MFI) as a secondary…
AMRA Medical continues to advance FSHD research with whole-body MRI measurements
AMRA’s recent publication demonstrates the utility of MRI-based muscle composite scores in neuromuscular disease clinical trials. AMRA Medical, a digital health company…
AMRA Biomarkers Indicate Individuals with CVD and T2D Have Faster Muscle Deterioration than Metabolically Disease-Free People — AMRA Medical to Present Data at SCWD
AMRA Medical will present “Two years of aging – initial results on changes in muscle composition in the UK Biobank imaging study”…